Flu vaccine mystery: why some shots work better than others
NCT ID NCT07240922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how getting the flu vaccine year after year changes your body's immune response. Researchers are testing two types of flu vaccines—a nasal spray (FluMist) and a shot (Flublok)—in 600 adults aged 22 to 50 in Hong Kong. They will measure antibodies and immune cells in the blood and nose to understand why some people get better protection than others.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Live attenuated influenza vaccine (FluMist) and recombinant hemagglutinin influenza vaccine (Flublok)
- What this could lead to
- If successful, this could help explain why some people respond better to flu vaccines than others, potentially leading to more effective vaccination strategies.
- What could go wrong
- This is a phase 4 study focused on immune response measurements, not on preventing flu itself. Results may not directly improve vaccine effectiveness or apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged 22-50 years at enrolment. 2. A. Participated in the DRIVE I or DRIVE II studies (for DRIVE IIIa). OR B. Did not participate in the DRIVE I or DRIVE II study (for DRIVE IIIb) and has not received influenza vaccination in the prior two years. 3. Capable of providing informed consent. 4. Resident in Hong Kong in the coming 2 years. Exclusion Criteria: 1. Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition ), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry). 2. With diagnosed medical conditions related to their immune system. 3. Currently taking medication for any condition that impairs immune system. 4. Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as: * Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; * Moderate or severe acute illness with or without fever after any previous influenza vaccination; or * A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination. 5. Individuals who report medical conditions not suitable to receive live attenuated vaccines, such as: * having asthma; * having close contact with severely immunosuppressed persons who require a protected environment; or * having immunosuppressive treatment (e.g. high-dose steroid, anti-cancer drugs and radiotherapy). 6. Individuals who report medical conditions not suitable to receive intramuscular injection, such as * Bleeding disorders * Habitually taking anticoagulants (with the exception of antiplatelets such as aspirin). 7. Individuals who have any medical conditions not suitable to receive inactivated or live attenuated influenza vaccines as determined by a clinician.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Influenza are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
School of Public Health, The University of Hong Kong
Hong Kong, Hong Kong, 00000, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- When the immune system Can't fight back: tracking three respiratory viruses
- Flu's journey: scientists track how influenza passes between people
- Can a stronger flu shot boost immunity in older adults?
- A nudge in the mailbox: could a letter boost flu shots for millions at risk?
- Can a new pill shorten the flu?
- Can a texted story boost flu shots for black kids?